The follow-on or copycat insulin glargine product Basaglar (Lilly) is similar to brand-name Lantus (Sanofi) in terms of efficacy and safety for the treatment of type 2 diabetes, but Basaglar cost less ...
[THE INVESTOR] Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on April 13, intent on challenging the original ...
Eli Lilly and Co. has negotiated the right to market a knockoff version of the world's top-selling insulin, Lantus. The deal opens the door for Lilly and its German partner, Boehringer Ingelheim, to ...
Medicare Part D may cover Basaglar, a long-acting insulin, and under the Inflation Reduction Act, the cost should not exceed $35 per month. The availability of Basaglar under Medicare Part D depends ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results